Organon Reports Positive Phase 3 Results for VTAMA Cream in Children With Atopic Dermatitis
Organon & Co. has announced new data from a sub-analysis of pooled Phase 3 ADORING 1 and ADORING 2 trials evaluating VTAMA® (tapinarof) cream, 1%, for the treatment of atopic dermatitis in children aged 2 to 17 years. The results indicate that VTAMA cream provided early and consistent skin clearance, as well as improvements in key atopic dermatitis measures, regardless of comorbidity status such as asthma, allergic rhinitis, or food allergies. The most frequently reported treatment-emergent adverse events in this pediatric population were folliculitis (7.8%), upper respiratory tract infection (4.6%), and headache (3.7%). Improvements in patient-reported outcomes, including sleep and itch relief, were observed as early as week 1 and maintained through week 8. These findings will be presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Orlando, Florida, on November 8, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251108738421) on November 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.